MHRA (UK) approves seladelpar (Livdelzi) to treat primary biliary cholangitis – CymaBay

The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has  16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called Primary Biliary Cholangitis (PBC), including pruritus. It works by controlling liver problems in the body and making the liver less inflamed.

Seladelpar belongs to a group of medicines called peroxisome proliferator-activated receptor delta agonists. The medicine can only be prescribed to adult patients with PBC, including pruritus, in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA